Real-Time Clinical Trials: Evidence, Governance, and Regulatory Readiness

The October 28, 2026, publication of Seixas’s commentary on real-time clinical trial governance prompted me to revisit a question raised by the FDA’s real-time clinical trials (RTCT) initiative: Can earlier regulatory access to trial information produce better decisions without compromising the integrity of the evidence? Industry perspectives differ. Some see an opportunity to strengthen oversight and development efficiency; others question its practical value, data reliability, and operational burden (Potter, 2026; Schell, 2026). I share the interest in identifying emerging safety concerns sooner and reducing avoidable delays for promising therapies. But technical feasibility should not be mistaken for demonstrated regulatory benefit. My focus is whether approaches developed for individual trials can scale without compromising study-specific safeguards or creating unnecessary burden.

The FDA’s April 28, 2026, announcement illustrates that distinction. The agency reported receiving and validating selected signals from AstraZeneca’s Phase II TRAVERSE trial through Paradigm Health, demonstrating that the technical framework for signal sharing worked in this proof of concept (U.S. Food and Drug Administration [FDA], 2026). It did not establish that clinical endpoints were fully validated or that patient safety, efficacy assessment, or approval timelines had improved. These outcomes remain to be evaluated before considering broader adoption.

An immediate consideration is the difference between an emerging signal and evidence ready to support a particular decision. A serious safety concern may warrant prompt evaluation, while an apparent efficacy trend may still require source review, endpoint adjudication, follow-up, and a defined analysis cut. Applicable investigational new drug (IND) safety-reporting duties under 21 C.F.R. § 312.32 remain in force; RTCT reporting does not replace them. The question is how sponsors and regulators distinguish signals requiring prompt attention from findings sufficiently mature to support regulatory conclusions.

That distinction also depends on what information is shared, who can access it, and how revisions are tracked. Reuters reported FDA officials’ description of an aggregated-signal model in which individual patient records remain with sponsors (Aboulenein, 2026). Such an approach may limit routine patient-level transmission, but it does not establish how privacy, access, retention, and audit controls would perform across a larger program. More frequent reporting could increase the volume of signals, corrections, and metadata that organizations must manage. The operational burden associated with broader implementation has not yet been established through publicly available pilot evaluations.

The operational challenge extends to data traceability. When a signal is corrected or updated, reviewers need to know which version, underlying data status, and analysis cut supported a conclusion. ICH E6(R3), Section 4.2, addresses data life-cycle controls, including metadata, corrections, transfers, and dataset finalization. It is nonbinding FDA guidance, not an RTCT-specific legal requirement (FDA, 2025). The question is how consistently these established principles can be applied across research sites, sponsors, technology providers, and regulators as reporting becomes more frequent.

Even accurately transmitted and traceable signals may not be ready for statistical inference. Continuous access to emerging data does not require continuous formal efficacy testing; repeated inferential analyses without prespecified safeguards can inflate false-positive findings. Bangdiwala and Yusuf (2025) describe methods for controlling repeated interim efficacy testing in Phase III randomized trials. Their work supports this methodological concern, not a claim that the FDA’s RTCT proofs of concept have experienced statistical failures.

These considerations lead to my principal recommendation: evaluate minimum, scalable sponsor–FDA reporting expectations while preserving trial-specific clinical and statistical requirements. The FDA has already established reporting criteria with individual proof-of-concept sponsors, and Paradigm Health has publicly described its Clinical Trial Reporting Schema and supporting data-management and review workflows (FDA, 2026; Paradigm Health, n.d.). My interest is in understanding how these approaches can be consistently implemented, evaluated, and scaled across different trials, sponsors, and research sites. Endpoint adjudication, safety triggers, data-maturity thresholds, and analysis cuts should remain tailored to each trial’s design, objectives, and regulatory requirements.

However, additional RTCT-specific reporting controls could duplicate existing GCP and IND safeguards, increase costs, slow information flow, and strain FDA reviewers or lower-resourced research sites. Seixas (2026) proposes separating operational monitoring, evidentiary review, and regulatory decision-making, together with evidence maturation and attention to infrastructure access. I see value in his proposed framework, particularly its emphasis on governance, but believe its practical implementation warrants further evaluation, including the operational demands of bidirectional review and data reconciliation. Any additional controls should remain proportionate to identified risks and build upon existing regulatory safeguards.

The evidence that would change my assessment is practical. A publicly available FDA–AstraZeneca debrief, together with broader pilot evaluations, could help determine whether existing mechanisms are sufficient or stronger safeguards are needed. Reliable reconciliation of corrected signals, appropriate clinical and statistical interpretation, manageable workload, protection of participant information, and meaningful safety or efficiency gains would increase my confidence in broader adoption. Conversely, recurring interpretation errors, unresolved version conflicts, or disproportionate operational burden would support a more cautious rollout. For now, I favor learning from these proofs of concept before scaling a model whose technical promise is evident but whose broader regulatory value remains unproven.